DE602006017694D1 - C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden - Google Patents

C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden

Info

Publication number
DE602006017694D1
DE602006017694D1 DE602006017694T DE602006017694T DE602006017694D1 DE 602006017694 D1 DE602006017694 D1 DE 602006017694D1 DE 602006017694 T DE602006017694 T DE 602006017694T DE 602006017694 T DE602006017694 T DE 602006017694T DE 602006017694 D1 DE602006017694 D1 DE 602006017694D1
Authority
DE
Germany
Prior art keywords
thrombotic
suffering
treatment
linked cyclic
receptor suitable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006017694T
Other languages
English (en)
Inventor
Carl Thibeault
James C Sutton
Jennifer X Qiao
Rejean Ruel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of DE602006017694D1 publication Critical patent/DE602006017694D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/43—Y being a hetero atom
    • C07C323/44—X or Y being nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
DE602006017694T 2005-06-27 2006-06-26 C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden Active DE602006017694D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69459705P 2005-06-27 2005-06-27
PCT/US2006/024911 WO2007002635A2 (en) 2005-06-27 2006-06-26 C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions

Publications (1)

Publication Number Publication Date
DE602006017694D1 true DE602006017694D1 (de) 2010-12-02

Family

ID=37450955

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006017694T Active DE602006017694D1 (de) 2005-06-27 2006-06-26 C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden

Country Status (6)

Country Link
US (1) US7700620B2 (de)
EP (1) EP1899299B1 (de)
AT (1) ATE485269T1 (de)
DE (1) DE602006017694D1 (de)
ES (1) ES2352796T3 (de)
WO (1) WO2007002635A2 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
JP2008526721A (ja) * 2004-12-30 2008-07-24 アステックス、セラピューティックス、リミテッド Ｃｄｋ、ｇｓｋ及びオーロラキナーゼの活性を調節するチアゾールおよびイソチアゾール誘導体
EP1833819A1 (de) 2004-12-30 2007-09-19 Astex Therapeutics Limited Pyrazolverbindungen, die die aktivität von cdk, gsk und aurora-kinasen modulieren
KR20070100894A (ko) * 2005-01-19 2007-10-12 브리스톨-마이어스 스큅 컴퍼니 혈전색전성 장애 치료용 ｐ2ｙ1 수용체 억제제로서의2-페녹시-ｎ-(1,3,4-티아디졸-2-일)피리딘-3-아민 유도체및 관련 화합물
ATE502924T1 (de) * 2005-06-27 2011-04-15 Bristol Myers Squibb Co Lineare harnstoffmimetika-antagonisten des p2y1- rezeptors zur behandlung von thromboseleiden
DE602006021306D1 (de) 2005-06-27 2011-05-26 Bristol Myers Squibb Co
US7714002B2 (en) * 2005-06-27 2010-05-11 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
JP5474354B2 (ja) 2005-12-30 2014-04-16 アステックス、セラピューティックス、リミテッド 医薬化合物
EP2049119A2 (de) 2006-06-29 2009-04-22 Astex Therapeutics Limited Pharmazeutische kombinationen von 1-cyclopropyl-3-[3-(5-morphoolin-4-ylmethyl-1h-benzoimidazol-2-yl)-1h-1-pyrazol-4-yl]-harnstoff
WO2008001101A2 (en) * 2006-06-29 2008-01-03 Astex Therapeutics Limited Pharmaceutical combinations
US7960569B2 (en) * 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
WO2009005638A2 (en) * 2007-06-27 2009-01-08 Merck & Co., Inc. Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors
EP3103791B1 (de) 2007-06-27 2018-01-31 Merck Sharp & Dohme Corp. 4-carboxybenzylamino-derivate als histondeacetylase-hemmer
EP2229383B1 (de) * 2007-12-04 2017-01-18 F. Hoffmann-La Roche AG Isoxazolo-pyrazin-derivate
US7943619B2 (en) * 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
SI2227467T1 (sl) 2007-12-04 2015-03-31 F. Hoffmann-La Roche Ag Derivati izoksazolo-piridina
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
CN102256964A (zh) 2008-10-02 2011-11-23 瑞斯比维特有限公司 p38MAP激酶抑制剂
CA2746357A1 (en) 2008-12-11 2010-06-17 Respivert Limited P38 map kinase inhibitors
WO2010079443A1 (en) 2009-01-12 2010-07-15 Pfizer Limited Sulfonamide derivatives
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
CN102573473B (zh) 2009-06-09 2015-05-27 加利福尼亚资本权益有限责任公司 用作hedgehog 信号转导抑制剂的异喹啉、喹啉和喹唑啉衍生物
EP2440057A4 (de) 2009-06-09 2012-12-05 California Capital Equity Llc Triazinderivate und deren therapeutische anwendungen
KR20120026612A (ko) 2009-06-09 2012-03-19 아브락시스 바이오사이언스, 엘엘씨 벤질 치환 트리아진 유도체와 이들의 치료적 용도
US8476039B2 (en) 2009-11-04 2013-07-02 Brajadulal Chattopadhyay Hot spring bacterial strain BKH1 and protein isolated therefrom, concrete compositions, and uses thereof
CN103002738A (zh) 2010-05-21 2013-03-27 英特利凯恩有限责任公司 用于激酶调节的化学化合物、组合物和方法
US9145407B2 (en) 2010-07-09 2015-09-29 Pfizer Limited Sulfonamide compounds
US8518177B2 (en) 2010-12-07 2013-08-27 Jadavpur University, West Bengal Materials and methods for the production of green concrete
FR2974576B1 (fr) * 2011-04-29 2013-07-19 Sanofi Aventis Derives de n-[(1h-pyrazol-1-yl)aryl]-1h-indole ou 1h- indazole-3-carboxamide, leur preparation et leurs applications en therapeutique
CA2842190A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
US8785470B2 (en) 2011-08-29 2014-07-22 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP2014528404A (ja) 2011-10-03 2014-10-27 レスピバート・リミテツド ｐ３８ＭＡＰキナーゼ阻害剤としての１−ピラゾリル−３−（４−（（２−アニリノピリミジン−４−イル）オキシ）ナフタレン−１−イル）尿素
EP2578582A1 (de) 2011-10-03 2013-04-10 Respivert Limited 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) Harnstoffe als p38 MAP Kinasehemmer
US8604062B2 (en) 2011-10-20 2013-12-10 Hoffman-La Roche Inc. Process for the preparation of isoxazolyl-methoxy nicotinic acids
US8785435B2 (en) 2011-10-20 2014-07-22 Hoffmann-La Roche Inc. Solid forms
EP2725025A1 (de) * 2012-10-26 2014-04-30 Sanofi Derivate von 1H-Indol-3-Carboxamid und ihre Verwendung als P2Y12 Antogonisten.
US9695198B2 (en) 2012-12-19 2017-07-04 Merck Sharp & Dohme Corp. Factor IXa inhibitors
EP2934537B1 (de) 2012-12-19 2018-04-04 Merck Sharp & Dohme Corp. Faktor-ixa-hemmer
EP2934538B1 (de) 2012-12-19 2021-03-31 Merck Sharp & Dohme Corp. Faktor-ixa-hemmer
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
CN110522731B (zh) 2014-02-14 2022-08-02 瑞斯比维特有限公司 作为抗炎化合物的芳族杂环化合物
AU2019344897B2 (en) 2018-09-18 2024-01-18 Nikang Therapeutics, Inc. Tri-substituted heteroaryl derivatives AS SRC homology-2 phosphatase inhibitors
CA3125353A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Inhibitors of menin-mll interaction
CA3125350A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Irreversible inhibitors of menin-mll interaction

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3118888A (en) 1964-01-21 Acylated s-triazines and process for their preparation
NL280954A (de) 1961-07-14
US4179563A (en) 1978-05-19 1979-12-18 Warner-Lambert Company 3-Aryloxy-substituted-aminopyridines and methods for their production
US4186199A (en) 1978-11-02 1980-01-29 American Hoechst Corporation Indolo-,1,2-dihydroindolo-, and 1,2,6,7-tetrahydroindolo [1,7-ab][1,5] benzodiazepines
EP0028489B1 (de) 1979-11-05 1983-10-05 Beecham Group Plc Enzym-Derivate und ihre Herstellung
JPS56166180A (en) 1980-05-28 1981-12-21 Chugai Pharmaceut Co Ltd Dibenzoxazepine derivative and its preparation
JPS56167649A (en) 1980-05-30 1981-12-23 Chugai Pharmaceut Co Ltd Diphenyl ether derivative
US4663453A (en) 1983-05-18 1987-05-05 Hoechst-Roussel Pharmaceuticals Inc. Benzo[b]pyrrolo[3,2,1-jk][1,4]benzodiazepines having dopamine receptor activity
US4761411A (en) 1983-05-18 1988-08-02 Hoechst-Roussel Pharmaceuticals Inc. Dihydrobenzopyrrolobenzodiazepines useful for treating pyschoses
JPS62280847A (ja) 1986-05-30 1987-12-05 Konica Corp 新規なマゼンタカプラ−を含有するハロゲン化銀写真感光材料
US4840947A (en) 1986-10-14 1989-06-20 Hoechst-Roussel Pharmaceuticals, Inc. Antiinflammatory and analgesic piperidin-4-yl-tetracyclic benzodiazepines and use thereas
JP2577222B2 (ja) 1987-04-10 1997-01-29 興和株式会社 新規な置換アニリド誘導体
JPH0339740A (ja) 1989-07-06 1991-02-20 Konica Corp 転写型熱現像カラー感光材料
JP2951434B2 (ja) 1991-04-18 1999-09-20 三菱製紙株式会社 電子写真感光体
NZ264063A (en) * 1993-08-13 1995-11-27 Nihon Nohyaku Co Ltd N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions
JP3395285B2 (ja) 1993-10-06 2003-04-07 日本製紙株式会社 感熱記録体
US5547966A (en) 1993-10-07 1996-08-20 Bristol-Myers Squibb Company Aryl urea and related compounds
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US6867045B1 (en) * 1994-11-14 2005-03-15 The Scripps Research Institute Method for diagnosis of thrombotic disorders
DE4443641A1 (de) 1994-12-08 1996-06-13 Bayer Ag Substituierte Carbonsäureamide
EP0809492A4 (de) * 1995-02-17 2007-01-24 Smithkline Beecham Corp Il-8 rezeptor antagonisten
TR199700993T1 (xx) 1995-03-20 1998-03-21 Eli Lilly And Company 5-ikameli-3-(1,2,3,6-tetrahidropridin-4-il)- ve 3-(piperidin-4-il)-1H-indoller: yeni 5-HT1F agonistler.
US6143764A (en) 1995-11-07 2000-11-07 Kirin Beer Kabushiki Kaisha Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same
AU714024B2 (en) 1996-03-25 1999-12-16 Eli Lilly And Company Tetrahydrobetacarboline compounds
WO1998018430A2 (en) 1996-10-30 1998-05-07 The University Of North Carolina At Chapel Hill P2y receptor antagonists
US6020357A (en) 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US6187797B1 (en) 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
US5858289A (en) 1997-02-24 1999-01-12 Global Consulting, Inc. Process for preparing compressed shape of ceramic fiber
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
WO2000077027A2 (en) 1999-06-14 2000-12-21 Tularik Limited Serine protease inhibitors
WO1999024035A1 (en) 1997-11-10 1999-05-20 Bristol-Myers Squibb Company Benzothiazole protein tyrosine kinase inhibitors
EP1047691A1 (de) 1997-12-12 2000-11-02 Smithkline Beecham Plc Chinolinpiperazin- und chinolinpiperidin derivate, deren herstellung und deren verwendung als kombinierte 5-ht1a, 5-ht1b und 5-ht1d rezeptor antagonisten
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
ATE297383T1 (de) 1997-12-22 2005-06-15 Bayer Pharmaceuticals Corp Hemmung der p38 kinase unter verwendung von symmetrischen und asymmetrischen diphenylharnstoffen
US6329395B1 (en) 1998-06-08 2001-12-11 Schering Corporation Neuropeptide Y5 receptor antagonists
ES2318899T3 (es) 1998-07-06 2009-05-01 Bristol-Myers Squibb Company Bifenil sulfonamidas como antagonistas duales de los receptores de angiotensina y endotelina.
HUP0104026A3 (en) 1998-10-06 2002-06-28 Dainippon Pharmaceutical Co 2,3-disubstituted pyridine derivatives, process for the preparation thereof, drug compositions containing the same and intermediates for the preparation
US7160887B1 (en) 1998-10-20 2007-01-09 Takeda Pharmaceutical Company Limited Aromatic amine derivatives, their production and use
GB9823873D0 (en) 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
ID30176A (id) 1999-03-12 2001-11-08 Boehringer Ingelheim Pharma Senyawa-senyawa yang bermanfaat sebagai zat anti-inflamasi
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
ID30460A (id) 1999-04-15 2001-12-06 Bristol Myers Squibb Co Inhibitor-inhibitor protein siklik tirosin kinase
CO5200760A1 (es) 1999-06-16 2002-09-27 Smithkline Beecham Corp Antagonistas del receptor de la il-8 ceptor il-8
JP2001089412A (ja) 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ベンゼン誘導体またはその医薬的に許容される塩
WO2001023358A1 (fr) 1999-09-27 2001-04-05 Sagami Chemical Research Center Derives pyrazole, intermediaires pour la preparation de ces derives, procedes de preparation des derives et intermediaires, et herbicides dont ces derives sont le principe actif
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
AU2001230913B2 (en) 2000-01-14 2005-06-30 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methanocarba cycloalkyl nucleoside analogues
WO2001055146A1 (en) 2000-01-29 2001-08-02 Lg Chem Investment Ltd. FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
JP2003521543A (ja) 2000-02-07 2003-07-15 アボット ゲーエムベーハー ウント カンパニー カーゲー ２−ベンゾチアゾリル尿素誘導体およびそのプロテインキナーゼ阻害剤としての使用
WO2001072751A1 (en) 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
US6586453B2 (en) 2000-04-03 2003-07-01 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
MXPA03006832A (es) 2001-01-31 2003-11-13 P & G Clairol Inc Nuevos agentes de acoplamiento para utilizarse en el tenido oxidativo del cabello.
WO2002064211A1 (en) 2001-02-09 2002-08-22 Merck & Co., Inc. Thrombin inhibitors
EP1461334A2 (de) 2001-04-27 2004-09-29 Vertex Pharmaceuticals Incorporated Pyrazolverbindungen als kinasehemmer
CN1518546A (zh) 2001-05-08 2004-08-04 ���ֹɷݹ�˾ 作为vegrf-2和vegfr-3抑制剂的选择性邻氨基苯甲酰胺吡啶酰胺
WO2003007955A2 (en) 2001-07-20 2003-01-30 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
US20040259875A1 (en) 2001-07-31 2004-12-23 Takeshi Yura Amine derivatives
AU2002342607B2 (en) 2001-08-06 2006-10-19 Pharmacia Italia S.P.A. Aminoisoxazole derivatives active as kinase inhibitors
PL204653B1 (pl) 2001-09-21 2010-01-29 Bristol Myers Squibb Co Pochodna pirazolo [3, 4-c] pirydyny, jej zastosowanie i kompozycja farmaceutyczna
AU2002352868A1 (en) 2001-11-27 2003-06-10 Merck & Co., Inc. 4-aminoquinoline compounds
JP2003192587A (ja) 2001-12-26 2003-07-09 Bayer Ag 尿素誘導体
EP1461311A2 (de) * 2001-12-26 2004-09-29 Bayer HealthCare AG Harnstoff-derivate als vr1-antagonisten
WO2003068223A1 (en) 2002-02-11 2003-08-21 Bayer Corporation Aryl ureas with raf kinase and angiogenesis inhibiting activity
EP2324825A1 (de) 2002-02-11 2011-05-25 Bayer Healthcare LLC Arylharnstoffe mit Angiogenese hemmender Aktivität
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
DE10213228A1 (de) 2002-03-25 2003-10-16 Bayer Ag Cyclopenten-Derivate
AU2003299472A1 (en) 2002-05-06 2004-07-22 Vertex Pharmaceuticals Incorporated Thiadiazoles or oxadiazoles and their use as inhibitors of JAK kinase
KR101116627B1 (ko) 2002-06-27 2012-10-09 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
JP2005537336A (ja) 2002-08-01 2005-12-08 ニューロサーチ、アクティーゼルスカブ 抗血管新生治療に応答する疾患の治療に有用な化合物
CN100497302C (zh) 2002-09-05 2009-06-10 神经研究公司 二芳基脲衍生物和它们作为氯通道阻滞剂的用途
EP1402888A1 (de) 2002-09-18 2004-03-31 Jerini AG Verwendung von substituierte carbozyclische Verbindungen als rotamase inhibitoren
US20040209930A1 (en) 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
JP2006507329A (ja) * 2002-11-21 2006-03-02 ニューロサーチ、アクティーゼルスカブ 新規アリールウレイド安息香酸誘導体及びその使用
US7056889B2 (en) 2002-12-16 2006-06-06 Kimberly-Clark, Worldwide, Inc. Compounds that bind P2Y2 or P2Y1 receptors
US7247654B2 (en) * 2003-06-04 2007-07-24 Bristol-Myers Squibb Company 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors
TWM252710U (en) 2003-07-18 2004-12-11 Huei-Chiun Shiu Annealing equipment
JPWO2005012221A1 (ja) 2003-08-04 2006-09-14 小野薬品工業株式会社 ジフェニルエーテル化合物、その製造方法および用途
EP1654225A4 (de) 2003-08-13 2007-11-28 Amgen Inc Antagonisten des melanin concentrating hormone-rezeptors
TW200523252A (en) 2003-10-31 2005-07-16 Takeda Pharmaceutical Pyridine compounds
KR101122708B1 (ko) 2003-12-26 2012-03-26 마사토시 하기와라 Ｓｒ 단백질 인산화 제어 방법, 및 유효성분으로서 ｓｒ 단백질 활성 제어제를 함유하는 항바이러스제
US7470712B2 (en) 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
WO2005113511A1 (en) 2004-05-12 2005-12-01 Bristol-Myers Squibb Company Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
JP4319958B2 (ja) 2004-09-15 2009-08-26 株式会社グリーンセイジュ 蒸留水製造システム
KR20070100894A (ko) 2005-01-19 2007-10-12 브리스톨-마이어스 스큅 컴퍼니 혈전색전성 장애 치료용 ｐ2ｙ1 수용체 억제제로서의2-페녹시-ｎ-(1,3,4-티아디졸-2-일)피리딘-3-아민 유도체및 관련 화합물
DE602006021306D1 (de) 2005-06-27 2011-05-26 Bristol Myers Squibb Co
US7714002B2 (en) 2005-06-27 2010-05-11 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
ATE502924T1 (de) 2005-06-27 2011-04-15 Bristol Myers Squibb Co Lineare harnstoffmimetika-antagonisten des p2y1- rezeptors zur behandlung von thromboseleiden

Also Published As

Publication number Publication date
WO2007002635A3 (en) 2007-03-29
US7700620B2 (en) 2010-04-20
ATE485269T1 (de) 2010-11-15
US20060293336A1 (en) 2006-12-28
EP1899299A2 (de) 2008-03-19
WO2007002635A2 (en) 2007-01-04
ES2352796T3 (es) 2011-02-23
EP1899299B1 (de) 2010-10-20
WO2007002635B1 (en) 2007-05-18

Similar Documents

Publication Publication Date Title
DE602006017694D1 (de) C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden
DE602006020871D1 (de) Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
TW200726764A (en) N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
WO2008048981A3 (en) Indole antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
ATE537170T1 (de) Cgrp-rezeptorantagonisten
NO20060195L (no) Kinolylamidderivater som CCR-5-antagonister
IS6902A (is) N-setin heterósýklísk NMDA/NR2B mótlyf sem ekki eru arýl
ATE433447T1 (de) Pyrimiidinverbindungen
ATE411323T1 (de) Cgrp-rezeptorantagonisten
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
EA200900606A1 (ru) Новые сульфониламидные производные в качестве антагонистов брадикининовых рецепторов
TW200638934A (en) Heteroaryl compounds as P2Y1 receptor inhibitors
EA200700099A1 (ru) Производные пиридина
NO20081844L (no) Terapeutiske forbindelser
NO20091741L (no) Pyrazolinforbindelser som mineralkortikoidreceptorantagonister
EA200900605A1 (ru) Новые производные фенилсульфамоил бензамидов в качестве антагонистов брадикининовых рецепторов
NO20082096L (no) Azaindol-2-karboksamidderivativer
DE602006018713D1 (de) Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns
ATE507880T1 (de) Cgrp-rezeptorantagonisten
PH12019500328A1 (en) Aza-indazole compounds for use in tendon and/or ligament injuries
DE602005007765D1 (de) Neue indol- oder benzimidazol-derivate
MXPA05013151A (es) 3-fluoro-piperidinas como antagonistas de n-metil-d-aspartato/nr2b.
ATE447575T1 (de) Selektive spirocyclische glucocorticoid-rezeptor- modulatoren
PH12019500327A1 (en) Indazole compounds for use in tendon and/or ligament injuries